Login
$IMDX
$1.65 -$0.21 (11.29%) Pre-market

$IMDX 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Results of Operations and Financial Condition
21 Sep 2026 8-K: Entry into a Material Definitive Agreement

This AMENDMENT NO. 2 TO AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER, dated as of September 15, 2026 (this “Amendment No. 2”), is entered into by and between Insight Molecular Diagnostics Inc. (formerly known as Oncocyte Corporation...

10 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

Discussions with FDA advance toward expected marketing authorization for GraftAssureDx

17 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

This SECOND AMENDMENT TO THE INSIGHT MOLECULAR DIAGNOSTICS INC. AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN (this “Amendment”), effective as of June 11, 2026, is made and entered into by Insight Molecular Diagnostics Inc., a Californ...

13 May 2026 8-K: Results of Operations and Financial Condition

Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement

30 Apr 2026 8-K: Other Events

Section 1.01 PRINCIPAL EXECUTIVE OFFICE. The principal executive office of the Corporation shall be located at such place within or without the State of California as shall be fixed from time to time by the board of directors, and if no ...

26 Mar 2026 8-K: Results of Operations and Financial Condition

Submitted GraftAssureDxTM for kidney transplant rejection testing for FDA review on Wednesday, March 25

26 Feb 2026 8-K: Entry into a Material Definitive Agreement

On February 20, 2026, Insight Molecular Diagnostics Inc. (the “Company”) entered into a Specimen Collection Agreement (the “Agreement”) with Quest Diagnostics Incorporated (“Quest Diagnostics”). Pursuant to the Agreement, Quest Diagnosti...

12 Feb 2026 8-K: Entry into a Material Definitive Agreement; Other Events

This Securities Purchase Agreement (this “Agreement”) is dated as of February 10, 2026, between Insight Molecular Diagnostics Inc., a California corporation (the “Company”), and each purchaser identified on the signature pages hereto (ea...

11 Feb 2026 8-K: Regulation FD Disclosure

Insight Molecular Diagnostics Inc. (the “Company”) intends, from time to time, to present, utilize, and/or at one or more meetings with investors or analysts a slide presentation, which is attached hereto as Exhibits 99.1. The Company un...

10 Nov 2025 8-K: Results of Operations and Financial Condition

On track to submit GraftAssureDx™ for FDA review by year-end

02 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

THIS AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”) is entered into as of September 29, 2025, by and between Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation (the “Company”), a California corporation located at...

19 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation

On September 16, 2025, the Board of Directors (the “Board”) of Insight Molecular Diagnostics Inc. (the “Company”) and the Compensation Committee of the Board approved increases to the annual base salaries of (i) Joshua Riggs, the Company...

11 Aug 2025 8-K: Results of Operations and Financial Condition

Transplant clinical trial has attracted leading transplant hospitals

02 Jul 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 27, 2025, Insight Molecular Diagnostics Inc. (the “Company”) held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”) virtually via live webcast at https://web.lumiconnect.com/259974801. Present at the Annual Meeting v...

17 Jun 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure

Section 1.01 PRINCIPAL EXECUTIVE OFFICE. The principal executive office of the Corporation shall be located at such place within or without the State of California as shall be fixed from time to time by the board of directors, and if no ...

12 May 2025 8-K: Results of Operations and Financial Condition

Q1 2025 pharma services revenue of $2.1 million, at 62% gross margin

17 Apr 2025 8-K: Changes in Registrant's Certifying Accountant

We have read the statements made by Oncocyte Corporation under Item 4.01 of its Form 8-K dated April 17, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other st...

24 Mar 2025 8-K: Results of Operations and Financial Condition

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million

10 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation

On March 4, 2025, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”), at the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), approved increases to the annual base salari...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support